Kornimate/medical-research-clean huggingface dataset:
transesophageal echocardiography: dysphagia risk in acute stroke (t.e.d.r.a.s. trial)

Conditions: Acute Stroke; Dysphagia; Swallowing Disorder

Summary: the prevalence of dysphagia in acute stroke patients undergoing transesophageal echocardiography (tee) is unknown. the aim of this study was to assess for the first time whether tee has a negative influence on swallowing in acute stroke patients.

dysphagia is common in patients with acute stroke and deteriorates the overall outcome (1). transesophageal echocardiography (tee) is a routine examination in the diagnostic workup of stroke etiology. in cardiac surgery it is known as cause of postoperative dysphagia (2). using flexible endoscopic evaluation of swallowing (fees) t.e.d.r.a.s., as a prospective, blinded, randomized and controlled study, includes patients in two groups in order to test the influence of tee on swallowing in acute stroke: an intervention group and a control group. fees is performed for analysis of swallowing in the intervention group (1) one day before tee, (2) 2-4 hours after tee, (3) 24 hours after tee. in the control group fees is performed on three consecutive days with tee taking place any time after the last fees. validated scores assess dysphagia severity in both groups.

Eligibility criteria:
inclusion criteria: * acute stroke (max. 7 days post-onset) as displayed by a cranial computed tomography (ct) or magnetic resonance imaging (mri) * written informed consent either by patients themselves or by a legal representative * indication for tee exclusion criteria: * brain hemorrhage * either pre-existing neurogenic dysphagia or * head-and-neck cancer induced dysphagia * dementia * aphasia with an impairment in language comprehension
schizophrenia sensory gating deficit with quetiapine

Conditions: Schizophrenia

Summary: the purpose of this study is the use of magnetoencephalography or meg (a machine that measures magnetic activity in your brain) and electroencephalography or eeg (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after three months of taking the antipsychotic medication quetiapine.

.problems with attention and perception are core features of schizophrenia and are hypothesized to result from defects in the filtering or gating of sensory input. examination of this requires neuoimaging techniques with high temporal resolution. high-density eeg and meg in combination with structural magnetic resonance imaging (smri) are used to map sensory gating. in a number of recent studies patient treated with novel antipsychotics have been shown to have p50 gating ratios resembling those of normal controls rather than that of schizophrenia subjects treatment with conventional antipsychotics. to date, there is no literature on the effects of quetiapine on sensory gating. subjects who meet all inclusion criteria and have been on a stable dose of quetiapine for three months will receive a clinical interview, an mri, meg, and neuropsychological testing to determine if patients with schizophrenia who are treated with quetiapine will demonstrate a sensory gating ratio similar to normal controls, indicating no deficit in sensory gating.

Eligibility criteria:
inclusion criteria: patient population * diagnosis of schizophrenia as determine by the structured clinical interview for dsm-iv * no comorbid diagnosis of ptsd * responders to quetiapine, determined by continuous treatment at the same dose of quetiapine and absence of psychiatric hospitalization for at least 3 months * no history of drug dependency in their lifetime * no history of alcohol or other substance abuse in the 6 months prior to entry into the study * no history of head injury with loss of consciousness for more than 5 minutes * no history of seizure disorder * no mood stabilizing agents * between 18-65 and * able to sign informed consent normal controls * matched in age and gender to patient population * no history of psychiatric dysfunction or alcohol or other substance dependence in their lifetime as determine by the scid * no history of alcohol or other substance abuse in the previous 6 months * no family history of psychotic disorder in first degree relatives as assessed by the fh-rdc diagnostic interview * no history of head injury with loss of consciousness for more than 5 minutes * no history of seizure disorder * between 18-65 * able to sign informed consent exclusion criteria: subjects will be excluded from participating in this study if they: * require treatment with a mood stabilizer * have had an inpatient hospitalization in the past 3 months * have a history of a neurological disorder * have any other axis i diagnosis besides schizophrenia

Keywords: psychiatry antipsychotic psychopharmacology clinical trial open label schizophrenia sensory gating attention memory
platelet function in hemodialysis patient

Conditions: Chronic Kidney Disease

Summary: the objective is to evaluate the function of the platelet in patients undergoing hemodialysis. the investigators will use the assay called pfa-100, an in vitro whole blood assay with three pathways of platelet activation to describe a platelet response profile. the hypothesis is that patients undergoing hemodialysis present a platelet dysfunction, that may be reversed by hemodialysis. the effect of heparin, used during hemodialysis session to anticoagulate the hemodialyzer, on platelet function will be assessed.

the aim of this study is to evaluate the platelet function during hemodialysis. one hundred patients with end-stage renal disease undergoing hemodialysis (2 to 3 sessions per week, 3 to 4 hours per session) will be included. patients who meet the inclusion criteria will be included after oral and written information and signature of written consent. the study consists in recording clinical and biological and the evaluation of platelet function by the pfa-100 assay. this is a whole blood platelet function assay, with 3 pathways of platelet activation (collagen-epinephrine, collagen-adp and specific p2y cartridge - innovance®). whole blood is collected in the arterial line of the arteriovenous vascular access (fistula or graft) before and after the hemodialysis session. pfa-100 is assayed within 2 hours after blood collection and the platelet response profile is interpreted according to the manufacturers instructions. clinical informations, especially hemorragic and thrombotic history, are collected the day of inclusion and 6 months after inclusion.

Eligibility criteria:
inclusion criteria : patient with end-stage chronic kidney disease undergoing hemodialysis age ≥ 18 years old hemodialysis on a peripheral vascular access (arteriovenous fistula or graft) hematocrit between 0.35 and 0.50 and platelet count between 150 and 500 g/l written consent after oral and written information exclusion criteria : pregnancy, breast feeding legal guardianchip hemodialysis on a catheter inability to sign the consent
apolipoprotein a-i gene polymorphism and atherosclerosis

Conditions: Coronary Arteriosclerosis; Cardiovascular Diseases; Heart Diseases; Atherosclerosis

Summary: to further define the linkage of the apo a-i gene polymorphism to genetic high density lipoprotein (hdl) deficiency and premature coronary artery disease. also, to utilize this gene marker to define the prevalence of genetic hdl deficiency in patients with premature coronary disease and to determine the relative risk of premature coronary disease associated with the apo a-i gene polymorphism.

background: apolipoprotein (apo) a-i is the major protein constituent of plasma high density lipoproteins (hdl). hdl has been shown to promote cholesterol efflux from cells in vitro. decreased plasma concentrations of hdl cholesterol and apo a-i have been associated with premature coronary artery disease due to atherosclerosis in our society. a genetic hdl deficiency, familial hypoalphalipoproteinemia, appears to be fairly common in patients with premature coronary artery disease. the gene for apo a-i has been isolated and characterized. preliminary studies indicate that a specific apo a-i gene polymorphism, detected following pst i restriction enzyme digestion utilizing a specific probe, is significantly more common in subjects with premature coronary artery disease than in normal control subjects, and in some kindreds is associated with genetic hdl deficiency. this apo a-i gene polymorphism is due to an alteration in the apo a-i, apo c-iii intergenic region, near the 3' end of the coding region for apo a-i. these observations have important implications for the detection of individuals genetically predisposed to premature coronary disease, as well as for providing insights into the mechanism leading to atherosclerosis. design narrative: questionnaires were used to obtain information from each patient on known risk factors and diet. fasting blood samples were obtained for lipoprotein analysis. standard clinical and cardiological information and fasting blood samples were also collected for the cases. blood was drawn for the dna studies. a determination was made as to whether the pst i apo a-i gene polymorphism was associated with diminished levels of plasma apo a-i or hdl cholesterol, by analysis of the distribution of these variables in cases and controls, after controlling for other known risk factors. linkage analysis was used to determine whether the pst i apo a-i gene polymorphism co-segregates with premature coronary disease, or with diminished levels of plasma apo a-i, or hdl cholesterol in 50 kindreds. a characterization was made of the abnormality in the apo a-i, apo c-iii, apo a-iv gene complex in patients with hdl deficiency, premature coronary disease, and the pst i apo a-i gene polymorphism.

Eligibility criteria:
no eligibility criteria
combination of paxil tablet and benzodiazepines

Conditions: Mental Disorders

Summary: this study was designed to assess the efficacy and safety of combination therapy of paxil and benzodiazepine anxiolytics. paxil tablet will be administered to patients with depression or depressive episodes who have received benzodiazepines for at least 4 weeks, and changes in the symptoms of depression will be evaluated by use of the rate and extent of decrease in hamilton rating scale for depression (ham-d).


Eligibility criteria:
inclusion criteria: * patients with depression or depressive episodes who are diagnosed to have major depressive disorders according to the dsm-iv criteria. * patients with 14 or higher points in total scores for items no.1 - 17 on ham-d. * patients who have continuously received benzodiazepine anxiolytics. exclusion criteria: * patients with a strong suicide tendency.

Keywords: depressive episodes paroxetine paxil depression benzodiazepine combination
vitamin d and functional outcomes after total hip arthroplasty (tha)

Conditions: Vitamin D Deficiency

Summary: the investigators would like to evaluate the effect of serum 25-hydroxy vitamin d level on post-operative short-term functional outcomes after total hip arthroplasty (tha). hypothesis: patients with low serum vitamin d level will have less within-patient improvement in pre- to 6 week, 1 year, 2 year and 5 year post tha womac scores, sf-36 scores, and performance-based tests(get up and go test and 2 minute walking test) compared to patients who do not have a low vitamin d levels. also, patients with low serum vitamin d level will have a higher rate of postoperative thigh pain or periprosthetic fracture.

vitamin d is an important nutrient to maintain both skeletal and non-skeletal function. in this study, we have 4 specific aims: the primary aim of this prospective observational study is to compare the pre- to 6 week, 1 year, 2 year and 5 year post-tha within-patient change in western ontario and mcmaster universities osteoarthritis index (womac) scores between patients who have a low preoperative serum vitamin d level and patients who do not have a low serum vitamin d level. low serum vitamin d will be defined as serum 25-hydroxy vitamin d level less than 32 ng/ml. the secondary aim is to compare the pre- to 6 week, 1 year, 2 year and 5 year post-tha within-patient change in performance-based tests (get up and go test, 2 minute walking test) between patients who have a low preoperative serum vitamin d level and patients who do not have a low serum vitamin d level. the third aim is to compare the pre- to 6 week, 1 year, 2 year and 5 year post-tha within-patient change in short-form 36 health survey (sf-36) scores between patients who have a low preoperative serum vitamin d level and patients who do not have a low serum vitamin d level. the fourth aim is to compare the rate of postoperative fracture or thigh pain between patients who have a low preoperative serum vitamin d level and patients who do not have a low serum vitamin d level. postoperative thigh pain is defined as pain at the anterolateral aspect of mid thigh which corresponds to the level of the prosthetic stem tip. thigh pain is characterized by pain in the start-up phase, diminishes during movement and is absent at rest.

Eligibility criteria:
inclusion criteria: * patients between the ages of 40 and 100 years old, and are scheduled for primary total hip arthroplasty with two surgeons (drs. sculco and cornell) at hospital for special surgery. * patients who have a serum 25-oh vitamin d drawn as part of their preoperative work-up. exclusion criteria: * bilateral one-stage total hip replacements * patients who required a complex surgical procedure including extensive bone grafting, osteotomy, extensive soft tissue release, or a need of adjunctive internal fixation with cables, wires or plate * those with serious medical co-morbidities that need adjusted rehabilitation protocol due to their medical problems * those who require immediate postoperative revision due to dislocation, infection or component malalignment
treatment of graft failure after hematopoietic stem cell transplantation

Conditions: Primary Graft Failure; Secondary Graft Failure

Summary: this is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (hsct). this regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (tbi) is designed to promote donor engraftment by day 42 after initial graft failure. the graft will consist of bone marrow or g-csf mobilized peripheral blood from a haploidentical related donor. the source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current university of minnesota blood and marrow transplantation program selection guidelines.


Eligibility criteria:
inclusion criteria: * patients with primary or secondary graft failure, as defined below, may receive a second transplant: * primary graft failure is defined as not achieving an anc ≥0.5x10\^9/l for three consecutive days by day 35 - 42 following the first transplant. * secondary graft failure is defined as achieving an anc ≥0.5x10\^9/l for three consecutive days by day 35 - 42, but subsequently drops below 0.5x10\^9/l without recovery. * loss of chimerism is defined as achieving an anc ≥0.5x10\^9/l for three consecutive, but with less than 10% cd15+ donor cells in the marrow or peripheral blood. * recipients should have acceptable organ function defined as: * renal: creatinine \ 30. for creatinine clearance \< 70, consultation with a bmt pharmacist is necessary for chemotherapy dose adjustments. * hepatic: bilirubin, ast/alt, alp \< 10 x upper limit of normal * cardiac: left ventricular ejection fraction \> 40% exclusion criteria: * uncontrolled infection at the time of transplant. * patients with fanconi anemia or other dna breakage syndromes.

Keywords: hematopoietic stem cell transplant
remotely monitored, mobile health supported multidomain rehabilitation program with high intensity interval training for covid-19

Conditions: COVID-19; Critical Illness; ICU Acquired Weakness; PICS; Cardiorespiratory Fitness

Summary: multicenter, prospective, randomized controlled trial providing mobile health supported physical rehabilitation to 120 patients who have been critically ill with covid-19 and who complete at least one exercise session.

remotely monitored, mhealth (remm) supported high intensity interval training (hiit) to improve recovery after hospital discharge in patients with covid-19 will evaluate the feasibility of clinical-, physiological- and patient-centered outcomes associated with a remotely monitored, mobile health-supported high intensity interval rehabilitation exercise training to improve the functional recovery of survivors who have experienced critical illness with covid-19 and have been discharged home from the hospital.

Eligibility criteria:
inclusion criteria: * primary diagnosis of covid-19 requiring hospital admission * discharged or expected to be discharged directly home from the hospital (not to a skilled nursing facility, inpatient rehabilitation center, or long-term acute care hospital) * able to ambulate with or without a gait aid prior to hospital discharge * age ≥ 18 years exclusion criteria: * hospital discharge \> 60 days unless readmitted to hospital in first 30 days, then 60 day window restarts and new exclusion is last hospital discharge \> 60 days * not ambulating independently prior to covid-19 illness (use of a gait aid permitted) * functional impairment resulting in inability to exercise at baseline * inability or unwillingness to comply with the study requirements or unable or unwilling to follow coaching via mobile-health iphone interaction * any absolute contraindications to exercise, including but not limited to: * recent (\< 5 days) acute primary cardiac event * unstable angina * uncontrolled dysrhythmias causing symptoms or hemodynamic compromise * uncontrolled hypertension over 255 mmhg systolic or 155 diastolic blood pressure * symptomatic aortic stenosis * uncontrolled symptomatic heart failure * acute myocarditis or pericarditis * suspected or known dissecting aneurysm * any adverse changes during gxt (i.e., persistent oxygen saturation drop below 88% while on prescribed oxygen therapy or significant hypotension such as mean arterial blood pressure \< 60 mmhg on 2 consecutive readings within 1 minute) * high risk for non-adherence as determined by screening evaluation * any condition, including cognitive impairment, that, in the judgment of the investigator, precludes participation because it could affect subject safety or ability of subject to complete the study * pregnant
women's heart attack research program: stress ancillary study

Conditions: Myocardial Infarction

Summary: the women's harp study is a multi-center study focusing on women with clinical presentation of myocardial infarction (mi). women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ecgs). 2 months following mi, participants will be screened for the stress ancillary study and enrolled if an elevated level of perceived stress is reported. after completing baseline assessments, participants will be randomized to enhanced usual care (euc) or stress management for 8 weeks. participants will be followed for 6 months.

women's harp is a multi-center, observational study which enrolls women with mi who are referred for cardiac catheterization. during the mi hospitalization, questionnaires will be administered to assess psychosocial stress leading up to the event (mi). participants will also have the option to enroll in the harp-stress ancillary study and harp-platelet sub-study. two months following mi, participants may be screened for the stress ancillary study. women with elevated perceived stress at screening will be enrolled. patients will complete baseline assessments (self-report questionnaires and 7 days of wrist actigraphy) and then will be randomized to group-based stress management or to enhanced usual care (euc). both study arms involve 8 weekly phone sessions delivered by trained facilitators. following intervention, participants in both study arms will repeat self-report questionnaires and 7 days of wrist actigraphy. anticipate enrollment of approximately 200 women to meet target of 144 qualified women.

Eligibility criteria:
inclusion criteria: * acute ischemic symptoms compatible with diagnosis of mi, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms * objective evidence of mi (either or both of the following): * elevation of troponin to above the laboratory upper limit of normal * st segment elevation of ≥1mm on 2 contiguous ecg leads * willing to provide informed consent and comply with all aspects of the protocol * age ≥ 21 years * female sex * pss-4 score ≥6 at 2 month follow up visit after mi exclusion criteria: * alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma. * moderately severe or severe depressive symptoms (phq-9 ≥ 15) * active suicidal ideation (phq-9 item #9 or otherwise reported during screening) * history of or current diagnosis of psychosis (ehr review) * significant cognitive impairment (ehr review or evident during screening) * current participation in another behavioral clinical trial.

Keywords: myocardial infarction women stress management
effectiveness of gastimunhp plus in supporting the treatment of peptic ulcer disease with helicobacter pylori infection

Conditions: Helicobacter Pylori Infection; Peptic Ulcer

Summary: challenges in the treatment of helicobacter pylori (h. pylori) include increasing antimicrobial resistance and patient's low tolerance to some regimens. lactobacillus johnsonii (l. johnsonii) and immunoglobulin y (igy) have been shown to decrease the amount and activity of h. pylori in human stomach and can increase patient's tolerance. we conduct a single-center double-masked randomized controlled trial to evaluate the effectiveness of gastimunhp plus (a product combining l. johnsonii and igy) in improving the clearance of h. pylori after six to eight weeks of treatment and side effects of h. pylori treatment. h. pylori is tested by c13- or c14-urea breath test.


Eligibility criteria:
inclusion criteria: * diagnosed with gastritis, duodenitis, or peptic ulcer. * tested positive with helicobacter pylori using c13- or c14-urea breath test or urease test. * indicated for helicobacter pylori eradication. exclusion criteria: * suspected malignant lesions. * children under 10 years of age; pregnant or lactating women. * allergic to chicken egg.

Keywords: helicobacter pylori peptic ulcer lactobacillus johnsonii immunoglobin y
randomized comparison between 3 d ct overlay and conventional fluoroscopy to decrease contrast and radiation exposure during cryoballoon ablation for atrial fibrillation

Conditions: Atrial Fibrillation

Summary: cryoablation using a balloon is an effective therapy for paroxysmal atrial fibrillation (af), however associated with significant amounts of radiation exposure and contrast medium use. a new imaging technique (3d ct overlay) could reduce radiation exposure and contrast medium use significantly.


Eligibility criteria:
inclusion criteria: - all patients screened are accepted for pvi according to the current guidelines - patients are candidates for enrolment if they have paroxysmal af as defined in the guidelines exclusion criteria: * persistent, long-standing persistent or permanent af * left atrial diameter \> 50 mm (measured in the parasternal long axis, as assessed with transthoracic echocardiography) * previous pvi ablation (epicardial or endocardial).